Nirogacestat hydrobromide - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for nirogacestat hydrobromide and what is the scope of patent protection?
Nirogacestat hydrobromide
is the generic ingredient in one branded drug marketed by Springworks and is included in one NDA. There are twenty-six patents protecting this compound. Additional information is available in the individual branded drug profile pages.Nirogacestat hydrobromide has eighty-nine patent family members in forty-five countries.
One supplier is listed for this compound.
Summary for nirogacestat hydrobromide
| International Patents: | 89 |
| US Patents: | 26 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Patent Applications: | 3 |
| DailyMed Link: | nirogacestat hydrobromide at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for nirogacestat hydrobromide
Generic Entry Date for nirogacestat hydrobromide*:
Constraining patent/regulatory exclusivity:
FOR ADULT PATIENTS WITH PROGRESSING DESMOID TUMORS WHO REQUIRE SYSTEMIC TREATMENT Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for nirogacestat hydrobromide
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Springworks | OGSIVEO | nirogacestat hydrobromide | TABLET;ORAL | 217677-001 | Nov 27, 2023 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Springworks | OGSIVEO | nirogacestat hydrobromide | TABLET;ORAL | 217677-003 | Apr 4, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Springworks | OGSIVEO | nirogacestat hydrobromide | TABLET;ORAL | 217677-001 | Nov 27, 2023 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Springworks | OGSIVEO | nirogacestat hydrobromide | TABLET;ORAL | 217677-001 | Nov 27, 2023 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Springworks | OGSIVEO | nirogacestat hydrobromide | TABLET;ORAL | 217677-002 | Apr 4, 2024 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Springworks | OGSIVEO | nirogacestat hydrobromide | TABLET;ORAL | 217677-003 | Apr 4, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for nirogacestat hydrobromide
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| African Regional IP Organization (ARIPO) | 2379 | Imidazole compounds for the treatment of neurodegenerative disorders. | ⤷ Sign Up |
| Colombia | 2022002731 | Formas en estado sólido de (s)-2-(((s)-6,8-diflúor-1,2,3,4-tetrahidronaftalen-2-il)amino)-n-(1-(2-metil-1-(neopentilamino)propan-2-il)-1h-imidazol-4-il)pentanamida y usos de la misma | ⤷ Sign Up |
| Uruguay | 28817 | COMPUESTOS DE IMIDAZOL PARA EL TRATAMIENTO DE TRASTORNOS NEURODEGERATIVOS | ⤷ Sign Up |
| Honduras | 2005000115 | COMPUESTOS DE IMIDAZOL PARA EL TRATAMIENTO DE TRASTORNOS NEURODEGENERATIVOS | ⤷ Sign Up |
| South Korea | 20240104138 | ⤷ Sign Up | |
| European Patent Office | 4426294 | COMPOSITIONS ET TRAITEMENTS À BASE DE NIROGACESTAT (COMPOSITIONS AND TREATMENTS WITH NIROGACESTAT) | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
